Publications by the researcher in collaboration with José Luis Pérez Gracia (19)

2020

  1. Intratumoral nanoplexed poly I:C BO-112 in combination with systemic anti-PD-1 for patients with anti-PD-1-refractory tumors

    Science Translational Medicine, Vol. 12, Núm. 565

2018

  1. Combined immunotherapy encompassing intratumoral poly-ICLC, dendritic-cell vaccination and radiotherapy in advanced cancer patients

    Annals of Oncology, Vol. 29, Núm. 5, pp. 1312-1319

2017

  1. Changes in serum interleukin-8 (IL-8) levels reflect and predict response to anti-PD-1 treatment in melanoma and non-small-cell lung cancer patients

    Annals of Oncology, Vol. 28, Núm. 8, pp. 1988-1995

2016

  1. Circulating melanoma exosomes as diagnostic and prognosis biomarkers

    Clinica Chimica Acta, Vol. 454, pp. 28-32

2015

  1. Nivolumab and urelumab enhance antitumor activity of human T lymphocytes engrafted in Rag2-/-IL2Rγnull immunodeficient mice

    Cancer Research, Vol. 75, Núm. 17, pp. 3466-3478

  2. Quantitative cell-free circulating BRAFV600E mutation analysis by use of droplet digital PCR in the follow-up of patients with melanoma being treated with BRAF inhibitors

    Clinical Chemistry, Vol. 61, Núm. 1, pp. 297-304

  3. Variations in molecular profile in NSCLC can be analyzed using cytological samples: Development of EGFR resistance mutations and coexistence of ALK-EML4 translocation in an EGFR-sensitive patient

    International Journal of Surgical Pathology, Vol. 23, Núm. 2, pp. 111-115

2014

  1. Randomized pharmacokinetic study comparing subcutaneous and intravenous palonosetron in cancer patients treated with platinum based chemotherapy

    PLoS ONE, Vol. 9, Núm. 2

  2. Relevance of MIA and S100 serum tumor markers to monitor BRAF inhibitor therapy in metastatic melanoma patients

    Clinica Chimica Acta, Vol. 429, pp. 168-174

  3. Serum interleukin-8 reflects tumor burden and treatment response across malignancies of multiple tissue origins

    Clinical Cancer Research, Vol. 20, Núm. 22, pp. 5697-5707

2012

  1. Immunostimulatory monoclonal antibodies for melanoma treatment

    Emerging Therapeutics for Melanoma (Future Medicine Ltd.), pp. 81-91

2011

  1. Assessment of epidermal growth factor receptor and krasmutation status in cytological stained smears of non-small celllung cancer patients: Correlation with clinical outcomes

    Oncologist, Vol. 16, Núm. 6, pp. 877-885

  2. Pilot clinical trial of type 1 dendritic cells loaded with autologous tumor lysates combined with GM-CSF, pegylated IFN, and cyclophosphamide for metastatic cancer patients

    Journal of Immunology, Vol. 187, Núm. 11, pp. 6130-6142

  3. Synergistic effects of CTLA-4 blockade with tremelimumab and elimination of regulatory T lymphocytes in vitro and in vivo

    International Journal of Cancer, Vol. 129, Núm. 2, pp. 374-386

2007

  1. Carcinoma microcítico de pulmón

    Revista de medicina, Vol. 51, Núm. 2, pp. 7-13

  2. Randomized crossover pharmacokinetic evaluation of subcutaneous versus intravenous granisetron in cancer patients treated with platinum-based chemotherapy

    Oncologist, Vol. 12, Núm. 9, pp. 1151-1155

  3. Small-cell lung cancer

    Revista de medicina de la Universidad de Navarra, Vol. 51, Núm. 2, pp. 7-13

2005

  1. Activity of gefitinib in central nervous system metastases in patients with non-small-cell lung center: Two case reports and a review of the literature

    Clinical Lung Cancer, Vol. 7, Núm. 2, pp. 138-140

  2. Assessment of the value of confirming responses in clinical trials in oncology

    European Journal of Cancer, Vol. 41, Núm. 11, pp. 1528-1532